LungLife AI, INC Notice of Results (1156I)

TIDMLLAI

RNS Number : 1156I

LungLife AI, INC

03 August 2023

LungLife AI, Inc.

(the "Company" or "LungLife")

Notice of Results

Investor Presentation

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, will announce its unaudited half-year report for the six months ended 30 June 2023 on Tuesday 8 August 2023.

Investor presentation

Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial Officer, will be hosting a live online presentation relating to the half-year report via the Investor Meet Company platform at 4.30pm (BST) on Tuesday 8 August 2023.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and register for the presentation here . Investors who already follow LungLife on the Investor Meet Company platform will automatically be invited.

A recording of the presentation and a PDF of the slides used will also be available on the LungLife website: https://investors.lunglifeai.com/media/

For further information please contact:

 
LungLife AI, Inc.                                                            www.lunglifeai.com 
Paul Pagano, CEO                                                                Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                                   Tel: +44 (0)20 7597 5970 
 & Joint Broker) 
Virginia Bull / Cameron MacRitchie 
 / Lydia Zychowska 
 
  Goodbody (Joint Broker)                                  Tel: +44 (0) 20 3841 6202 / +353 (1) 
  Tom Nicholson / Stephen Kane                                                         667 0420 
Walbrook PR Limited                       Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com 
Paul McManus / Alice Woodings / Phillip                    Mob: 07980 541 893 / 07407 804 654 / 
 Marriage                                                                         07867 984 082

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSSFFIEEDSEDA

(END) Dow Jones Newswires

August 03, 2023 02:00 ET (06:00 GMT)

Lunglife Ai (LSE:LLAI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024